statement
領展先前已動用了14億港元的資產處置所得,這些資金源自出售彌敦道700號(交易額23億港元)以及出售Market Street 100號50%的股權(交易額2.26億澳元)。
A statement by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.
領展先前已動用了14億港元的資產處置所得(這些資金源自出售彌敦道700號-交易額23億港元,以及出售 Market Street 100號50%的股權-交易額2.26億澳元)。
Discussion
Related claims
領展先前已動用了14億港元的資產處置所得,這些資金源自出售彌敦道700號(交易額23億港元)以及出售 Market Street 100號50%的股權(交易額2.26億澳元)。瑞銀 · statement交易完成後,領展將於新加坡管理3個零售資產,包括東福坊、裕廊坊及宏茂橋坊。信報 · predictionAfter the transaction is completed, 領展 will manage three retail assets in Singapore: Eastpoint Mall, Jurong Point and AMK Hub.領展房產基金 · prediction交易完成後,領展將於新加坡管理三個零售資產,包括東福坊、裕廊坊及宏茂橋坊。領展房產基金 · prediction交易完成後,領展將於新加坡管理三個零售資產,包括東福坊、裕廊坊及宏茂橋坊。領展 · prediction領展資產管理宣布向英康保險收購新加坡東福坊50.1%權益,代價為2.395億新加坡元,折合約14.7億港元。領展資產管理 · statement
More claims by 瑞銀
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.predictionTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.statement
All claims by 瑞銀